Literature DB >> 27930934

Cognitive remediation for negative symptoms of schizophrenia: A network meta-analysis.

Matteo Cella1, Antonio Preti2, Clementine Edwards3, Tabitha Dow3, Til Wykes3.   

Abstract

Cognitive remediation (CR) is a treatment targeting cognitive difficulties in people with schizophrenia. Recent research suggested that CR may also have a positive effect on negative symptoms. This meta-analysis investigates the effect of CR on negative symptoms. A systematic search was used to identify all randomized-controlled trials of CR in people with schizophrenia reporting negative symptoms outcomes. Levels of negative symptoms at baseline, post-therapy and follow-up, sample demographics and treatment length were extracted. Study methodological quality and heterogeneity were addressed. Negative symptoms standardized mean change was calculated using Hedges's g and used as the main outcome. The search identified 45 studies reporting results for 2511 participants; 15 studies reported follow-up outcomes. CR was associated with a reduction of negative symptoms (most conservative model g=-0.30; 95% CI: -0.36, -0.22) at post-therapy compared with treatment as usual and this effect was larger at follow-up (g=-0.36; 95% CI: -0.51, -0.21). Drop-out rate was comparable between conditions. Network meta-analysis confirmed CR was superior to TAU and TAU plus active control or adjunctive treatment. No evidence of publication bias was found. Studies with more rigorous methodology were associated with larger negative symptom reduction (g=-0.40; 95% CI: -0.51 to -0.30). Although negative symptoms have not been considered a primary target for CR, this intervention can have small to moderate beneficial effects on this symptom cluster. Future research should explore in detail the active mechanisms responsible for negative symptom reduction and the relationship between cognitive and negative symptoms in schizophrenia.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27930934     DOI: 10.1016/j.cpr.2016.11.009

Source DB:  PubMed          Journal:  Clin Psychol Rev        ISSN: 0272-7358


  54 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 2.  Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia.

Authors:  Samuel A Barnes; Andre Der-Avakian; Jared W Young
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

3.  Contemporary approaches in mental health rehabilitation.

Authors:  L van der Meer; C Wunderink
Journal:  Epidemiol Psychiatr Sci       Date:  2018-07-25       Impact factor: 6.892

4.  Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics.

Authors:  Irene Bighelli; Claudia Leucht; Maximilian Huhn; Cornelia Reitmeir; Felicitas Schwermann; Sofia Wallis; John M Davis; Stefan Leucht
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

5.  The clinical characterization of the patient with primary psychosis aimed at personalization of management.

Authors:  Mario Maj; Jim van Os; Marc De Hert; Wolfgang Gaebel; Silvana Galderisi; Michael F Green; Sinan Guloksuz; Philip D Harvey; Peter B Jones; Dolores Malaspina; Patrick McGorry; Jouko Miettunen; Robin M Murray; Keith H Nuechterlein; Victor Peralta; Graham Thornicroft; Ruud van Winkel; Joseph Ventura
Journal:  World Psychiatry       Date:  2021-02       Impact factor: 49.548

6.  Early-Stage Negative Symptom Trajectories and Relationships With 13-Year Outcomes in First-Episode Nonaffective Psychosis.

Authors:  Wing Chung Chang; Ryan Wui Hang Ho; Jennifer Yee Man Tang; Corine Sau Man Wong; Christy Lai Ming Hui; Sherry K W Chan; Edwin M H Lee; Yi Nam Suen; Eric Y H Chen
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

7.  Validity and utility of Hierarchical Taxonomy of Psychopathology (HiTOP): I. Psychosis superspectrum.

Authors:  Roman Kotov; Katherine G Jonas; William T Carpenter; Michael N Dretsch; Nicholas R Eaton; Miriam K Forbes; Kelsie T Forbush; Kelsey Hobbs; Ulrich Reininghaus; Tim Slade; Susan C South; Matthew Sunderland; Monika A Waszczuk; Thomas A Widiger; Aidan G C Wright; David H Zald; Robert F Krueger; David Watson
Journal:  World Psychiatry       Date:  2020-06       Impact factor: 49.548

8.  Compensatory Cognitive Training for psychosis: Effects on negative symptom subdomains.

Authors:  Zanjbeel Mahmood; Jillian M R Clark; Elizabeth W Twamley
Journal:  Schizophr Res       Date:  2018-10-04       Impact factor: 4.939

9.  Executive dysfunctions differentially predict amotivation in first-episode schizophrenia-spectrum disorder: a prospective 1-year follow-up study.

Authors:  Wing Chung Chang; Jasmine Tsz Ting Liu; Christy Lai Ming Hui; Sherry Kit Wa Chan; Edwin Ho Ming Lee; Yi Nam Suen; Eric Yu Hai Chen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-06-22       Impact factor: 5.270

10.  Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: Revisiting the relevance of human coaching and elucidating interplay between multiple outcomes.

Authors:  Lana Kambeitz-Ilankovic; Linda T Betz; Clara Dominke; Shalaila S Haas; Karuna Subramaniam; Melisa Fisher; Sophia Vinogradov; Nikolaos Koutsouleris; Joseph Kambeitz
Journal:  Neurosci Biobehav Rev       Date:  2019-09-23       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.